Delayed Primary Closure Using Negative Pressure Wound Therapy

Sponsor
Medical College of Wisconsin (Other)
Overall Status
Recruiting
CT.gov ID
NCT04042259
Collaborator
(none)
350
1
2
27.9
12.5

Study Details

Study Description

Brief Summary

Surgical site infection rates for contaminated or dirty laparotomy wounds can be as high as 45%. Surgical management of dirty and contaminated wounds has been controversial in the literature and between surgeons. Primary closure (PC) of these wounds can lead to multiple complications including surgical site infection (SSI), necrotizing soft tissue infection, wound and fascial dehiscence, evisceration, sepsis and hernia development. However, an alternative technique of utilizing secondary intention results in prolonged healing time and increased cost and healthcare resource utilization. Delayed primary closure (DPC) was developed to address many of these issues. Bhangu completed a systematic review and meta-analysis comparing primary versus delayed primary skin closure in contaminated and dirty abdominal wounds. They included 8 studies randomizing 623 patients with contaminated or dirty abdominal wounds to either DPC or PC. The most common diagnosis was appendicitis (77.4%), followed by perforated abdominal viscus (11.5%), ileostomy closure (6.5%), trauma (2.7%), and intra-abdominal abscess/other peritonitis (1.9%). The time to first assessment for DPC was between 2 and 5 days postoperatively. In all studies, the DPC group had significantly less SSIs using a fixed-effect model (odds ratio, 0.65; 95%CI, 0.40-0.93; P = .02). However, heterogeneity was high (72%), and using a random-effects model, the effect was no longer significant (odds ratio, 0.65; 95% CI, 0.25-1.64; P = .36). Additionally, all of the studies were found to be at high risk of bias, with marked deficiencies in study design and outcome assessment.

A recent systematic review showed improved fascial closure rates with negative pressure wound therapy (NPWT) Yet, a large national study using NPWT to perform a DPC has been shown to actually decrease the rate of closure. Access to NPWT has increased over the years and innovative wound management techniques including incisional application of negative pressure therapy have allowed clinicians to apply this method to dirty wounds following the principles of delayed primary closure. There are currently no studies available to help determine the safety and efficacy of advanced NPWT techniques to optimize surgical wound management from the open abdomen to skin closure. Within our Division, we have decided to make a practice change and develop a standard closure plan for open abdomens using the negative pressure devices available within our institution.

Condition or Disease Intervention/Treatment Phase
  • Device: Abthera
  • Procedure: Open adbdomen for post-laparotomy without NPWT device
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
350 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Delayed Primary Closure Using Negative Pressure Wound Therapy
Actual Study Start Date :
Aug 3, 2020
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Negative Pressure Wound Therapy

Standardized wound closure with negative pressure therapy.

Device: Abthera
Negative Pressure Wound Therapy Device
Other Names:
  • VERAFLO
  • Prevena
  • Other: Historic Cohort

    Historic cohort have undergone a midline laparotomy and managed with an open abdomen for at least one day and have contaminated or dirty wound classification.

    Procedure: Open adbdomen for post-laparotomy without NPWT device
    Historic cohort treatment of open abdomen for dirty wounds without use of negative pressure therapy device

    Outcome Measures

    Primary Outcome Measures

    1. 30 day wound complication rate [30 days]

      Wound infection, dehiscence, evisceration

    2. 30 day readmission [30 days]

      Patient discharged and readmitted to primary care

    3. Days of Abthera, VERAFLO, and Prevena use [through wound closure, an average of 30 days]

      Use of negative pressure wound therapy

    4. Closure of Fascia [7 days]

      Measure of days to closure of fascia

    5. Closure of Skin [7 days]

      Measure of days to closure of skin

    6. Cost of care [days to wound closure an average of 30 days]

      Total cost for wound care

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • 18 years or older

    • undergone midline laparotomy and managed with an open abdomen for at least one day

    • contaminated or dirty wound classification

    Exclusion Criteria:
    • Less than 18 years of age

    • Prisoners

    • Pregnant females

    • Non-surgical patients

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Froedtert Hospital Milwaukee Wisconsin United States 53226

    Sponsors and Collaborators

    • Medical College of Wisconsin

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Colleen Trevino, Assistant Professor, Medical College of Wisconsin
    ClinicalTrials.gov Identifier:
    NCT04042259
    Other Study ID Numbers:
    • PRO00032783
    First Posted:
    Aug 1, 2019
    Last Update Posted:
    Nov 22, 2021
    Last Verified:
    Nov 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 22, 2021